Citi Reaffirms Their Hold Rating on Medipal Holdings (MEPDF)
Don't Miss TipRanks' Half Year Sale
Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
According to TipRanks, Yamaguchi is an analyst with an average return of -2.6% and a 37.50% success rate. Yamaguchi covers the Healthcare sector, focusing on stocks such as Astellas Pharma, Chugai Pharmaceutical Co, and Sumitomo Dainippon Pharma Co.
The word on The Street in general, suggests a Hold analyst consensus rating for Medipal Holdings with a $17.21 average price target.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Morgan Stanley Says a New Bull Market Is Underway — Here Are 2 Stocks to Bet on It
Despite recent economic headwinds, a resilient corporate earnings backdrop and better-than-feared data offer some optimism. Still, with July's weak jobs report and signs that inflation may remain stubborn, the big question now is: where will the markets go? Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Watching the situation from Morgan Stanley, chief US equity strategist Mike Wilson is taking an upbeat view. He believes that we're in a bull market – although he describes it as distinct from last year's run. In a recent interview with Bloomberg, Wilson opined: 'We think the bear market ended in basically April. It was a pretty nasty one. There were several along the way, and that was the final flush. And now we're in a new bull market. And capital markets activity is just another sign that that analysis or that conclusion is probably correct… Volatility in bull market or bear market is normal. I mean, you want to see some consolidation… but I want to be very clear, it's still early in the new bull market, so you want to be buying these dips… You have supportive policy, you have positive rate of change, you have good flow dynamics. I mean, those are all the ingredients you need.' With that bullish framework in mind, Morgan Stanley's stock analysts are zeroing in on stocks they believe can thrive in this bull market. We've looked into the data from the TipRanks platform to find out how the Street sees these picks; here's a closer look alongside the Morgan Stanley commentary. Dutch Bros (BROS) The first stock we'll look at is Dutch Bros, the Phoenix-based drive-through coffee chain that was founded as a family-owned pushcart business in Oregon in 1992, opened its first franchise location in 2000, and went public in 2021. The company's expansion started in the Pacific Northwest, but today the company has locations in the Southeast and is extending into the Great Lakes region. The company's menu features a wide range of drinks, from plain coffee to coffee-based specialty drinks to non-coffee favorites such as lemonade or hot chocolate. Dutch Bros also offers a range of seasonal drinks, and basic snacks including muffin tops and granola bars. An app-based rewards program lets customers earn points toward free drinks or place their orders ahead of time for pick-up. The company also offers a gift card program, both digitally and through physical cards. Dutch Bros has proven popular in the years since its founding, and the chain currently boasts 1,043 locations, both franchised and company-owned, across 19 states. The total location count includes 725 that are company-owned and operated, and another 318 that are franchised. Year-over-year, in 2Q25, the location count reflected a 14% increase from 2Q24. The company's network expansion included 113 company-owned stores, and 18 franchise stores. This expansion was reflected in Dutch Bros' quarterly financial results, which showed strong growth YoY and beat the top- and bottom-line forecasts. In the 2Q25 report, the company's revenue grew 28% year-over-year to reach $415.8 million and to beat expectations by $12.2 million. The company's non-GAAP earnings figure, at 26 cents per share, was up 7 cents per share from the prior year and was 8 cents better than had been anticipated. Dutch Bros finished Q2 with $254.4 million in cash and other liquid assets available. For Morgan Stanley analyst Brian Harbour, Dutch Bros' chief attraction is its overall strength. He wrote of the company after the earnings report, 'A strong quarter across the board from BROS continues the recent string of success for the company, and reinforces our prior confidence in the outlook, which we think sets up well into FY26. We'd expect it to support the stock after it has become modestly more debated of late. Both comps and new store productivity came in ahead of expectations again as BROS' sales drivers continue to work in concert, with the food push still ahead. This flowed through to profits, aided by G&A managed well, labor leverage, and some food cost favorability (dairy offsetting coffee), while new unit openings were aligned with our thinking and remain on track for the year.' Looking ahead, Harbour rates BROS as Overweight (i.e., Buy), with a price target of $84 that suggests a one-year upside potential of 24.5%. (To watch Harbour's track record, click here) Overall, BROS has earned a Strong Buy consensus rating from Wall Street's analysts, based on 16 recent reviews that include 15 Buys and 1 Hold. The shares are priced at $67.48 and their average price target, $82.73, implies a gain of 23% by this time next year. (See BROS stock forecast) Globe Life (GL) The second Morgan Stanely pick we'll look at is Globe Life, one of the many firms that together form the backbone of the US insurance industry. Globe Life has been in business since 1900, and today has a market cap of nearly $11.6 billion. While there are much larger firms in the US insurance sector, Globe still has a large footprint – in 2024, the company paid out a total of $1,856,086,935 in claims. The figure included more than $1 billion in life insurance claims, and another $781 million-plus in health insurance claims. Life insurance forms the core of Globe's business; as the company tells its customers, these policies exist to protect families from financial stress at the worst of times. In addition to traditional life insurance policies, the company also offers mortgage protection insurance, designed to protect family homes as well as financial assets. Outside of life insurance, Globe also offers supplemental health insurance policies, including coverage for cancer treatments, critical illnesses, hospital and ICU stays, and accidents. Included in the company's health coverage line-up are Medicare supplemental policies, to back up the coverage offered under the government program. Globe also offers business plans, providing coverage for employees under various life and medical policies. In the past two years, Globe Life has faced headwinds in the form of government investigations – by both the SEC and the DOJ. Both investigations focused on claims of misleading or fraudulent sales practices – but in July of this year, the company announced that both the SEC and the DOJ had closed their cases without taking or recommending enforcement action. The closure of these investigations eased worries about uncertainties toward GL's share performance, and the stock has gained 15% in the last 30 days. Globe Life reported its 2Q25 results last month, and the results were mixed. The company had total revenue of $1.48 billion, for a 3% year-over-year gain – although it missed the forecast by almost $25 million. Globe's bottom line, the net operating income per diluted common share, came in at $3.27, a total that was 2 cents better than the estimates and was up from the figure of $2.97 per share reported for 2Q24. Bob Huang covers this stock for Morgan Stanley, and he sees the easing of investigatory pressures as the key point for Globe Life. 'The multiple contraction last ~18 months was due to DOJ and SEC investigation on sales practices and uncertainties around Health segment earnings. With these headwinds recently removed, we believe the thesis should shift back to fundamentals and steady earnings growth. As such, we believe the relative earnings certainty, and capital light business model should support long term share price appreciation. We see a path for the multiple on Globe Life shares to expand from 9.5x back to the historical 11.0x average,' Huang noted. These comments support Huang's Overweight (i.e., Buy) rating on GL shares, while his $166 price target points toward an upside potential of 19% on the one-year horizon. (To watch Huang's track record, click here) The Strong Buy consensus rating on GL is derived from 10 reviews with a lopsided split of 9 Buys and 1 Hold. The shares are currently trading for $139.05 and the $156.11 average price target indicates a 12% upside potential in the next 12 months. (See GL stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment. Disclaimer & DisclosureReport an Issue Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
3 hours ago
- Business Insider
Texas Sues Eli Lilly (LLY) for Allegedly Bribing Doctors to Prescribe Its Drugs
The U.S. State of Texas has launched a lawsuit against Eli Lilly (LLY), alleging that the pharmaceutical giant bribed doctors to prescribe its medications. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Texas Attorney General Ken Paxton announced the lawsuit on Aug. 12, claiming that Eli Lilly has been 'bribing' doctors and other medical providers to prescribe its medications for their patients. The state further claims that Eli Lilly bribed and illegally induced medical providers to prescribe its most profitable drugs, including the weight-loss medicine Zepbound. 'Big Pharma compromised medical decision-making by engaging in an illegal kickback scheme,' said Attorney General Paxton in announcing the lawsuit that seeks unspecified damages from Eli Lilly. The pharma company did not immediately respond publicly to the Texas lawsuit. Fraud and Abuse The lawsuit states that the Texas Attorney General aims to hold drug manufacturers accountable for fraud and abuse. Last year, the Texas Attorney General's office sued insulin manufacturers, including Eli Lilly, and pharmacy benefit managers alleging that they colluded to artificially raise the price of insulin. The lawsuit in Texas comes as LLY stock has been reeling after the company issued clinical trial results for its new weight-loss pill that came in below Wall Street's expectations. Following the trial results being made public, Eli Lilly's share price fell 15% for its biggest decline since the 2008 financial crisis. Is LLY Stock a Buy? The stock of Eli Lilly has a consensus Strong Buy rating among 21 Wall Street analysts. That rating is based on 17 Buy and four Hold recommendations issued in the last three months. The average LLY price target of $946.89 implies 51.35% upside from current levels.
Business Insider
4 hours ago
- Business Insider
Is CSCO Stock a Buy? TipRanks AI Analyst Says Yes
Cisco Systems stock (CSCO) has earned an Outperform rating from TipRanks' A.I. Stock Analysis tool. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Cisco attracts strong interest from investors and Wall Street analysts. Notably, TipRanks' A.I. Analyst also gave Cisco a positive rating, signaling confidence in the stock's potential. The tool assigns an Outperform rating on Cisco stock with a solid score of 78. Meanwhile, the A.I. analyst assigns a price target of $73 to CSCO stock, implying an upside of over 3% from the current levels. For context, TipRanks' A.I. Stock Analysis provides automated, data-backed evaluations of stocks across key metrics, offering users a clear and concise view of a stock's potential. CSCO's Financial Strength Our AI analyst states that Cisco Systems demonstrates robust financial performance with strong profitability and cash flow, underpinning its stability in the communication equipment industry. It explains that the positive momentum aligns well with strategic growth in AI infrastructure and partnerships. Indeed, Cisco is uniquely positioned to facilitate AI deployment with its networking and security portfolios, as well as Silicon One. In addition, product innovation is a strength with the company announcing noteworthy new offerings, including a Unified Cloud Management platform and Hybrid Mesh Firewall. Overall, our AI egghead believes that Cisco is well-positioned for growth, though investors should remain mindful of external challenges such as tariffs and sector-specific headwinds. However, as can be seen above it is not all good news for Cisco. There are macroeconomic risks and some uncertainty around the stock given its failure to disclose AI revenue numbers. There are also some technical and valuation concerns – as seen below. The technical indicators suggest caution due to potential overbought conditions. Valuation remains a concern due to a higher P/E ratio, yet the company's dividend yield adds some long-term investment appeal. What Other Analysts Say David Vogt of UBS raised the firm's price target on Cisco to $74 from $70 and kept a Neutral rating on the shares. He said that increasing campus and data center demand should drive a beat when it reports Q4 earnings this week. JPMorgan analyst Samik Chatterjee raised the firm's price target on Cisco to $78 from $73 and kept an Overweight rating on the shares. The firm adjusted price targets in hardware and networking, saying it expects upside to second half of 2025 estimates from 'robust' cloud spending. However, underlying end market drivers for other customer verticals 'remain a watchpoint' as they exhibit more sensitivity to the economic environment. Is CSCO a Good Stock to Buy Now?
